BHCM
MLTX icon

Brevan Howard Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Brevan Howard Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$606K Sell
32,507
-46,131
-59% -$764K 0.01% 1187
2025
Q4 		$1.04M Buy
+78,638
New +$928K 0.01% 750

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brevan Howard Capital Management's MLTX Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 59% in Q1 2026, selling an estimated $764K and leaving 32,507 shares worth $606K. The position accounts for 0.01% of the portfolio, ranked #1187.

Brevan Howard Capital Management first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.04M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Brevan Howard Capital Management held 32,507 shares of MoonLake Immunotherapeutics worth $606K as of Q1 2026.
  • Brevan Howard Capital Management sold 46,131 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $764K.
  • MoonLake Immunotherapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1187 holding.
  • Brevan Howard Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's MoonLake Immunotherapeutics position peaked at $1.04M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.